(WSJ) – Shanghai is a favored destination, with lower costs than the West and innovation in biotechnology

CAR-T therapy, short for chimeric antigen receptor T-cell therapy, was pioneered in the U.S. Today, however, Shanghai is emerging as a favored destination for patients from America and other rich countries—a testament not only to China’s low costs but also to the country’s emergence as an innovator in biotechnology. (Read More)